The FDA has given a 27 March 2021 review date for Bristol-Myers Squibb’s multiple myeloma cell therapy ide-cel, just in time to meet a contingent value right (CVR) due to Celgene shareholde
Bristol-Myers Squibb and bluebird bio have refiled their CAR-T therapy for multiple myeloma, leaving the outcome of a three drug “bet” with former Celgene shareholders dependent on a fast r
Gilead’s $11.9 billion purchase of Kite Pharma in 2017 didn’t follow the script, with two big write-downs in the value of the asset since then, but a fresh approval for a CAR-T
Our round-up of recent biotech financings is headed by a sizeable $200 million third round for Zenas BioPharma, with Cellectis, Reunion Neuroscience, Karius, Context Thera
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.